title: Well-differentiated pancreatic islet cell carcinoma: Is there reversibility in mTOR inhibitor resistance?
authors.forename: Thomas
authors.initials: T
authors.lastname: Walter
authors.forename: Jean-Yves
authors.initials: JY
authors.lastname: Scoazec
authors.forename: Christophe
authors.initials: C
authors.lastname: Couderc
authors.forename: Julien
authors.initials: J
authors.lastname: Forestier
authors.forename: Colette
authors.initials: C
authors.lastname: Roche
authors.forename: Jean-Alain
authors.initials: JA
authors.lastname: Chayvialle
authors.forename: Catherine
authors.initials: C
authors.lastname: Lombard-Bohas
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D018273:Carcinoma, Islet Cell / Q000188:drug therapy* / Q000473:pathology; D002454:Cell Differentiation; D019008:Drug Resistance, Neoplasm / Q000187:drug effects / Q000502:physiology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors*
chemical_list: D047428:Protein Kinase Inhibitors; D058570:TOR Serine-Threonine Kinases